| abstract |
1.- A salt characterized in that it is selected from: Maleic acid salt of (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazole-1-yl ) -3-cyclopropanitrile; y (R) -3- (4- (7 H -pyrrolo [2,3-d] pyrimidin-4-yl) -1 H -pyrazol-1-yl) -3-cyclopropanitrile sulfuric acid salt; y (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopropanitrile phosphoric acid salt.2.- Salt according to claim 1 characterized in that it is (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3 maleic acid salt -cyclopentylpropanitrile. 3. The salt according to claim 1 characterized in that it is sulfuric acid salt of (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H- pyrazol-1-yl) -3-cyclopentylpropanitrile. 4. The salt according to claim 1 characterized in that it is phosphoric acid salt of (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin) -4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanitrile. 5. The salt according to claim 1 characterized in that it is substantially isolated. 6. A method for preparing a salt according to any of the claims. 1 to 5 characterized in that it comprises combining (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanitrile conác maleic acid, sulfuric acid or phosphoric acid. 7. A composition characterized in that it comprises at least one salt in accordance with any of claims 1 to 5 and at least one pharmaceutically acceptable carrier. 8.- The composition in accordance with claim 7 characterized in that it is suitable for oral or topical administration.9.- The composition according to claim 7 characterized in that it is suitable for topical administration.10.- A method for modulating a JAK activity characterized in that it comprises contacting JAK with a salt in accordance with any of claims 1 to 5.11.- The method according to claim 10 characterized in that the modulation is inhibition.12.- A method for treating a disease in a patient characterized in that the disease is associated with the activity of JAK, which comprises administering to the patient a therapeutically effective amount of a salt in accordance with cu any of claims 1 to 5. |